organization · Reporting owner
6 Dimensions Capital, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fulcrum Therapeutics, Inc.
Report date July 22, 2019 · Filed July 22, 2019
Section 16 reporting ended · disclosed 2019-07-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 559,821 |
Ending reported balance
After 2019-07-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-07-22 · Conversion · Acquired 441,071 · Balance 441,071 F1: On July 22, 2019 the Series B Preferred Stock converted into Common Stock on 7:1 basis upon the closing of the issuer's initial public offering without payment of consideration. The shares had no expiration date. Row 2 · 2019-07-22 · Purchase · Acquired 118,750 · Balance 559,821 |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-07-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-22 · Conversion · Disposed 3,087,500 · Balance 0 F1: On July 22, 2019 the Series B Preferred Stock converted into Common Stock on 7:1 basis upon the closing of the issuer's initial public offering without payment of consideration. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 22, 2019 the Series B Preferred Stock converted into Common Stock on 7:1 basis upon the closing of the issuer's initial public offering without payment of consideration. The shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2019 Filed Jul 22, 2019 16:32 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | ConversionSeries B Preferred Stock · Derivative | 3,087,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-041307 · a4.xml · derivative · entry 3 6 Dimensions Capital, L.P. · CIK 0001717958 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 441,071 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 22, 2019 the Series B Preferred Stock converted into Common Stock on 7:1 basis upon the closing of the issuer's initial public offering without payment of consideration. The shares had no expiration date. F1 · derivative.exercise_date: On July 22, 2019 the Series B Preferred Stock converted into Common Stock on 7:1 basis upon the closing of the issuer's initial public offering without payment of consideration. The shares had no expiration date. F1 · derivative.expiration_date: On July 22, 2019 the Series B Preferred Stock converted into Common Stock on 7:1 basis upon the closing of the issuer's initial public offering without payment of consideration. The shares had no expiration date. Read SEC document |
| July 22, 2019 Filed Jul 22, 2019 16:32 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 118,750 | $16.00 | $1,900,000.00 |
DisclosureSEC source: 0001104659-19-041307 · a4.xml · nonDerivative · entry 2 6 Dimensions Capital, L.P. · CIK 0001717958 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,821 Read SEC document |
| July 22, 2019 Filed Jul 22, 2019 16:32 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | ConversionCommon Stock | 441,071 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-041307 · a4.xml · nonDerivative · entry 1 6 Dimensions Capital, L.P. · CIK 0001717958 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 22, 2019 the Series B Preferred Stock converted into Common Stock on 7:1 basis upon the closing of the issuer's initial public offering without payment of consideration. The shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.